Patients receiving moderately emetogenic chemotherapy (MEC) are commonly prescribed a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist (RA) and dexamethasone (DEX) as standard-of-care (SOC) antiemetic prophylaxis. However, in patients with an elevated risk of chemotherapy-induced nausea and vomiting (CINV) due to individual risk factors, prophylaxis with an neurokinin-1 (NK1) RA-containing regimen may optimise their antiemetic prevention. To address this unmet need for a…
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial☆
Annals of Oncology | | A. Molassiotis, K. Jordan, M. Karthaus, G. Dranitsaris, E.J. Roeland, L. Schwartzberg, V. Stimamiglio, A. Alonzi, S. Olivari Tilola, E. Bonizzoni, E. Brozos Vázquez, T. Buchler, Y. Cheng, D.C. Christoph, P. García Alfonso, X. Lu, M. Majem, D. Mavroudis, K. Syrigos, E. Tomlins, Z. Zhou, M. Zimovjanová, M. Aapro
Topics: cervical-cancer, chemotherapy, prevention